Sofosbuvir‐containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment

Background and Aims This study aimed to assess the safety and efficacy of sofosbuvir (SOF)‐based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results. Methods This is a real‐life multicentre retrospective co...

Full description

Saved in:
Bibliographic Details
Published in:Liver international 2020-04, Vol.40 (4), p.797-805
Main Authors: Eletreby, Rasha, El‐Serafy, Magdy, Anees, Mahmoud, Kasem, Gamal, Salama, Marwa, Elkhouly, Reham, Hamdy, Mostafa, Abdel Haleem, Hisham, Kamal, Ehab, Abdel‐Razek, Wael, Salama, Rabab, Elshenawy, Mohamed, Shafeek, Ayman, Hassany, Mohamed, El‐Sayed, Manal H., El‐Shazly, Yehia, Esmat, Gamal
Format: Article
Language:English
Subjects:
Cirrhosis
Diabetes mellitus
Dialysis
efficacy
Epidermal growth factor receptors
Failure analysis
Hepatitis
Hepatitis C
Impairment
Kidney diseases
Liver
Liver cirrhosis
Multivariate analysis
Renal function
renal impairment
Response rates
Safety
sofosbuvir
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims This study aimed to assess the safety and efficacy of sofosbuvir (SOF)‐based regimens in patients with moderate to severe renal impairment; a subject which has been questioned by many investigators with conflicting results. Methods This is a real‐life multicentre retrospective cohort study on 4944 chronic Hepatitis C virus (HCV) patients with chronic kidney disease (CKD) (eGFR
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.14299